Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tenomodulin (TNMD)
- Target
- TNMD
- Molecular classification
- Type II transmembrane glycoprotein, Marker of tendon and ligament cells (tenocytes, ligamentocytes), BRICHOS domain-containing protein, Anti-angiogenic protein, Other: Related to chondromodulin-1 (Chm1)
01
Overview
Tenomodulin is a tendon- and ligament-specific type II transmembrane glycoprotein found predominantly in tenocytes, ligamentocytes, tendon stem/progenitor cells, and periodontal ligament cells. It plays central roles in tissue maturation, cell proliferation, and maintenance of tendon and ligament homeostasis. Tenomodulin contains a conserved BRICHOS domain and an anti-angiogenic, cysteine-rich C-terminal region analogous to chondromodulin-1. Its expression is largely restricted to hypovascular tissues, and its loss impairs tenocyte proliferation and collagen matrix organization. Genome-wide associations implicate TNMD in metabolic and neurodegenerative diseases, but its principal characterization is within connective tissues. Although no drugs currently target this protein, it is intensively studied as a potential regenerative marker and regulator in tendon biology
- Other names
- TNMDTendinMyodulinTeMBRICD4CHM1L
02
Mechanism of action
Not defined for known drugs, since direct pharmacological targeting is unreported. Experimental approaches focus on modulation (e.g., knockout/overexpression) to observe tissue repair or anti-angiogenic effects
03
Biological functions
Tendon/ligament maturationRegulation of tendon stem/progenitor cells (TSPCs)Cell proliferation (promotion in tenocytes, ligandocytes)Inhibition of angiogenesis (anti-angiogenic function)Tissue homeostasis and regenerationNegative regulation of osteogenesis, chondrogenesis, adipogenesis in mesenchymal stem cells
04
Disease associations
Tendonopathy and tendon pathologiesLigament degenerationObesity (TNMD SNPs association)Age-related macular degeneration (SNP association)Alzheimer’s disease (SNP association)Other: Tissue injury, tendon rupture
05
Safety considerations
No major therapeutic safety concerns described due to the absence of direct drugs targeting tenomodulin. However, knockout models show impaired tendon maturation, reduced cell density, and abnormal collagen accumulation, indicating its essential role in tendon integrity and function
06
Biomarkers
Tenomodulin (TNMD) itself serves as a biomarker for mature tenocytes, ligamentocytes, and tendon stem/progenitor cells (TSPCs) for lineage tracing and tissue health
Beyond the preview
Go deeper on Tenomodulin (TNMD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tenomodulin (TNMD).